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Background and Purpose:  The influence of specific brain lesions on health-related quality 
of life (HRQoL) after acute ischemic stroke (AIS) is uncertain.  We aimed to identify 
imaging predictors of poor HRQoL in alteplase-treated participants of the alteplase-dose arm 
of the Enhanced Control of Hypertension and Thrombolysis Stroke study (ENCHANTED). 
Methods:  ENCHANTED was an international trial of low- versus standard-dose intravenous 
alteplase in AIS patients, with functional outcome (modified Rankin scale [mRS]) and 
HRQoL on the 5-dimension European quality of life scale (EQ-5D) assessed at 90 days post-
randomization.  Brain images were analysed centrally by trained assessors.  Multivariable 
logistic regression was undertaken in the study population randomly divided (2:1) into 
training (development) and validation (performance) groups; with age (per 10-year increase), 
ethnicity, baseline National Institutes of Health stroke scale (NIHSS) score, diabetes mellitus, 
pre-morbid function (mRS score 0 or 1) and proxy respondent, forced into all models.  Data 
are presented with odds ratios (OR) and 95% confidence intervals (CI). 
Results:  Eight prediction models were developed and validated in 2526 AIS patients 
(median age 67.5 years; 38.4% female; 61.7% Asian) with complete brain imaging and 90-
day EQ-5D utility score data.  The best performance model included acute ischemic changes 
in the right (OR 1.69, 95%CI 1.24-2.29) and deep (OR 1.50, 95%CI 1.03-2.19) middle 
cerebral artery regions. 
Conclusions:  Right-sided and deep ischemia predicts poor HRQoL after AIS.  Further 
research is required to understand mechanisms and appropriate rehabilitation strategies to 
optimise outcomes after thrombolysed AIS. 




Acute ischemic stroke (AIS) reduces health-related quality of life (HRQoL) in patients and 
families from disruption of activities and roles in relation to disability, cognitive dysfunction, 
and mood disorders[1].  Many predictors of poor post-stroke HRQoL have been identified 
that include: older age[2-6], female sex[2, 5], non-white ethnicity[3, 5, 7], single marital 
status[6, 8], low education[9], poor socio-economic status[5], diabetes mellitus[3, 10], greater 
neurological damage severity[3, 4], depression and/or anxiety[6, 8, 11-15], physical[16] and 
cognitive[17] impairment[9], disability[11], incontinence[3], proxy-respondents[2, 18-20], 
poor residential status[21, 22], lack of social support[8, 9, 23], poor social participation[14, 
22, 24, 25], and inadequate coping strategies[26-28].  In addition, several brain imaging signs 
- infarct volume[29, 30], subcortical damage[31, 32], microbleeds[33], white matter 
change[34], and small vessel disease[35] - have been shown to be associated with poor 
HRQoL, but only a few as independent predictors generated by developing and validating 
prediction models, possibly due to low statistical power from small studies.  Our aim was to 
identify brain imaging predictors of poor HRQoL among AIS patients who were treated with 
alteplase and participated in the alteplase-dose arm of the international Enhanced Control of 
Hypertension and Thrombolysis Stroke Study (ENCHANTED).  This large multi-ethnic 
clinical cohort that underwent standardized measures and central adjudication of brain images 
afforded us the opportunity to develop and validate various multivariable models.   
Methods 
Data sharing  
Individual patient data used in these analyses can be shared by request from any qualified 




ENCHANTED was a multicentre, international, 2x2 quasi-factorial, prospective, randomized, 
open, blinded outcome trial that investigated the effects of low- vs. standard-dose intravenous 
alteplase, and intensive vs. guideline-recommended blood pressure (BP) lowering, in 
thrombolysis-eligible AIS patients, the details of which are outlined elsewhere[36-40].  This 
paper pertains to patients of the alteplase-dose arm, which was completed earlier and had all 
brain imaging analyses finalised before those in the BP lowering arm of the trial.  The 
alteplase-dose arm included 3310 AIS patients randomly assigned to low-dose (0.6mg/kg; 
15% as bolus, 85% as infusion over 1 hour) or standard-dose (0.9mg/kg; 10% as bolus, 90% 
as infusion over 1 hour) intravenous alteplase.  The study protocol was approved by the 
appropriate ethics committee at each participating centre, and written informed consent was 
obtained from each patient or an appropriate surrogate.  The study is registered with 
Clinicaltrials.gov (number NCT01422616). 
Outcomes 
Demographic and clinical characteristics, including estimated pre-morbid function (modified 
Rankin scale [mRS] scores 0 or 1; patients with scores >1 were excluded) were recorded at the 
time of enrolment (baseline).  Neurological severity was assessed using the National Institutes 
of Health stroke scale (NIHSS) at baseline, 24 hours, and Day 3 (or earlier on discharge from 
hospital).  The primary outcome for the main trial was functional status on the mRS, assessed 
by telephone or in-person, by trained independent researchers at 90 days.  The primary outcome 
of these analyzes was the 3 level version of the 5-dimension European quality of life scale (EQ-
5D) which defines general health states across five dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) according to three levels of severity (1=no 
problems, 2=some/moderate problems, and 3=severe problems)[41].  Ratings on each subscale 
of the EQ-5D are synthesized into a single utility score using UK population-based preference 
weights[42, 43].  Utility scores vary from -0.594 to 1; 1 representing perfect health, 0 death, 
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and negative scores health states considered worse than death[43].  For these analyses, ‘poor 
HRQoL’ was defined as scores of 2 or 3, defining problems within each dimension of EQ-5D 
or an overall health utility score ≤0.7 (mean).   
Uncompressed images of brain computed tomography (CT), magnetic resonance imaging 
(MRI) and angiography at baseline and at 24-36 hours follow-up were uploaded into the study 
brain imaging database in Digital Imaging and Communications in Medicine (DICOM) format 
identified only by patient’s unique study number.  Where multiple baseline scans were 
available for a patient, our analysis preference for assessments was the following: (1) non-
contrast CT over plain CT images from CT angiogram or perfusion studies; (2) CT scans with 
thick slices over those with thin slices; (3) scanning time closest to time of randomization; and 
(4) MRI when this was the only imaging conducted at baseline.  Acute/old ischemic changes 
and location were confirmed and/or justified based on follow-up scans where available.  
Analysis of the non-hemorrhagic component of the images was conducted by a research team 
with a background in neurology (1 neuroradiologist, 8 stroke neurologists, and 2 stroke 
neurology trainees) and standardized training via the ACCESS training module 
(www.ed.ac.uk/edinburgh-imaging/access).  More details about the imaging analyses are 
reported elsewhere[44].  In these analyzes, acute ischemic changes were classified according 
to a standard proforma[45].  Side of ischemic change was classified as right, left, or middle of 
the brain, and location was categorized according to three groups: middle cerebral artery 
(MCA) including any lesion in this vascular territory; anterior cerebral artery (ACA); and 
posterior cerebral artery (PCA) covering infratentorial locations such as brainstem, cerebellum, 
or both.  For patients with multiple locations, they were included in each of the location 
categories.  MCA was further classified as left or right side, and deep location.  Mass effect 
was defined as the swelling compressing or displacing surrounding tissues, and graded 
according to a widely validated 7-point ordinal scale[46], with 0 indicating no swelling and 
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scores from 1 to 6 indicating progressive increases in the size of swelling.  The Alberta Stroke 
Program Early CT Score (ASPECTS)[47] measured the extent of ischemia in a range of 0-10: 
10 representing no evidence of early ischemic change; 1 point being subtracted from 10 for any 
evidence of early ischemic change across defined regions of the MCA territory; and 0 
indicating diffuse involvement throughout the MCA territory.  An ASPECTS >7 was 
considered ‘high’ in these analyzes, according to other studies[48-50].  A large lesion was 
defined as the whole of the periphery, overall MCA territory, whole MCA and PCA territory, 
whole MCA and ACA territory, or all three vascular territories.  The presence of tissue 
hypoattenuation, which indicates irreversible damage, was defined as either grey matter 
attenuation equal to normal white matter, or grey and white matter attenuation less than normal 
white matter[51].  Atrophy was present if there was any evidence of reduction in brain tissue 
volume, but grey and white matter volumes were not separately measured.  White matter 
change included any periventricular white matter lucencies, hyperintensities, or both.  Any 
presence of atrophy, white matter changes, or old infarct, was considered as background 
damage or ‘frailty’. 
Statistical analysis 
Complete case analysis was used in developing various prediction models; patients with any 
missing values were excluded.  The study population was randomly divided (2:1 ratio) into 
training (develop prediction models) and validation (validate predictive model performance) 
groups.  Age (per 10-year increase), ethnicity, baseline NIHSS score, history of diabetes 
mellitus, pre-morbid mRS (0 or 1) and proxy respondent, were selected a priori[52] to be 
forced into all models.  Alteplase dose and onset to needle time did not show any significant 
association with HRQoL, hence these variables were not included in any model for these 
analyzes.  Imaging features used to develop prediction models included acute ischaemic 
change (yes/no; right, left, middle; MCA , ACA and/or PCA, infratentorial locations; MCA 
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territory left, right; MCA territory deep), mass effect, ASPECTS >7, large infarct, 
hyperattenuated/abnormal vessel sign, tissue hypoattenuation, atrophy, white matter changes, 
old infarct, and any background damage.   
Multivariable logistic regression was used to develop models using different combinations of 
variables according to different selection methods: in stepwise selection, the significance 
level for entry of a variable was set at P <0.2, whereas the significance level for a variable 
staying was P <0.05, and; for forward and backward selection, the significance level for 
variable entry was set as P <0.05.  Collinearity between variables were checked.  Regression 
coefficients for models were estimated with maximum likelihood methods.   
Discriminative ability of models was assessed using the concordance (C) statistic, which 
provides a range of 0.5-1.0[53]: 0.5 represents a model no better than chance; >0.7 represents 
a good model; >0.8 represents a strong model; and 1 represents perfect fit for a model 
predicting an outcome.  Receiver operating characteristic (ROC) curves and the Hosmer-
Lemeshow goodness of fit test (P <0.05 indicates poor prediction or lack of fit) were used for 
comparisons of the performance of models in the development and validation datasets.  
Calibration plots provided visualisation of the level of agreement between observed and 
predicted probabilities: a calibration (fit) curve lying closely to the ideal line indicates that the 
model fits well with the data; a calibration curve away, or with systematic deviation, from the 
ideal line indicates that the model is not a good fit for the data.  Bootstrapping of 1000 
population samples simulated using random sampling with replacement was used to estimate 
the variability and precision of parameter estimates in the optimal models[54, 55].  Sampling 
distribution of regression coefficients were demonstrated in scatter plots, showing both 
variability of regression coefficients and correlated coefficients.  Data are presented with 
odds ratios (OR) and 95% confidence intervals (CI), and the significance level was set at 
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P<0.05 without adjustment for multiplicity.  All analyses were undertaken using SAS 
enterprise (7.1).   
Results 
A total of 2526 ENCHANTED AIS patients (median age 67.5 years; 38.4% female; 61.7% 
Asian) had complete brain imaging data and 90-day EQ-5D utility scores available for 
analyzes (Figure 1).  Included patients were less likely to be Asian, had milder neurological 
severity and had differences in their medical history and presumed AIS etiology when 
compared to excluded patients (Supplemental Table S1).  Table 1 shows the characteristics of 
patients classified by good and poor HRQoL based on the utility score.  Patients with poor 
HRQoL were significantly older, more proportion of female and non-Asian, had greater 
neurological impairment, more frequency of co-morbidities (hypertension, acute coronary 
syndrome, atrial fibrillation, diabetes mellitus and hypercholesterolaemia), pre-stroke 
disability (mRS score 1), current medication use (antihypertensive, aspirin, glucose-lowering, 
and statin agents), early ischemic change, right-sided lesions, in the MCA territory, with mass 
effect, poorer ASPECTS score (<7), and were more likely to show infarction, 
hyperattenuated/abnormal vessel sign, tissue hypoattenuation, and background changes.  
There were no significant differences in the characteristics of patients in the training 
(n=1685) and validation (n=841) groups (Supplemental Table S2). 
Eight different models were developed with significant imaging features selected and forced 
clinical factors (Supplemental Table S4): Models 1 and 4 included acute ischemic change in 
the right hemisphere; Model 2 included acute ischemic change in the middle and acute 
ischemic change in right hemisphere; Model 3 included acute ischemic change in the left 
hemisphere, mass effect, and tissue hypoattenuation; Model 5 included acute ischemic 
change in the left MCA territory, mass effect, and tissue hypoattenuation; Model 6 included 
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acute ischemic change in the right MCA territory; Model 7 included acute ischemic change in 
the deep and right MCA territory, and; Model 8 included acute ischemic change in the left 
MCA territory and mass effect. 
The performance of the various models was assessed in the validation dataset.  Calibration 
plots show that the fit lines and 95% CI for all the models, except Model 8, provide close 
coverage to the ideal line (Figure S1).  However, the best calibration performance was for 
Model 7 which had a smoother fit line and less under-estimation of probability compared to 
the other models.  Overall, though, there was consistency in the discrimination performance 
of models (C range 0.736 to 0.741; Figure S2), and all models except Model 8, had similar 
calibration and discrimination performance (Supplemental Figures S3 and S4).  Table 2 
shows the best fitted model Model 7, which included acute ischemic change in the right MCA 
territory (OR 1.69, 95% 1.24-2.29) and in the deep MCA territory (OR 1.50, 95%CI 1.03-
2.19).  From the 1000 simulated population samples using the bootstrapping technique, there 
was close and equal scattering of the parameter estimates in the training dataset, indicating 
good precision (Supplemental Table S5, Figure S5).  
Table 3 shows results of multivariable logistic regression for predictors on various EQ-5D 
domains, with adjustment for baseline NIHSS scores and use of proxy respondents.  Tissue 
hypoattenuation was significant for two domains: positive for poor mobility (OR 1.7, 95% CI 
1.08-2.68) and negative for pain/discomfort (OR 0.60, 95% 0.39-0.93).  Atrophy and white 
matter change also showed significant positive associations with poor mobility (OR 1.24, 
95% CI 1.02-1.51 and OR 1.52, 95% CI 1.25-1.86, respectively).  There were significant 
associations between each marker of background damage and poor self-care, and impaired 
usual activity: atrophy (OR 1.26, 95% CI 1.01-1.56 and OR 1.33, 95% CI 1.09-1.61, 
respectively); white matter change (OR 1.29, 95% CI 1.04-1.60 and OR 1.26, 95% CI 1.03-
1.54, respectively) and old infarct (OR 1.24, 95% CI 1.01-1.52 and OR 1.34, 95% CI 1.11-
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1.62, respectively).  However, no imaging features were associated with anxiety/depression.  
Complete Transparent Reporting of a multivariable prediction model for Individual Prognosis 
or Diagnosis (TRIPOD) checklist[56] is outlined in Supplemental Table S6.  
Discussion 
In these post-hoc analyses of a large multi-ethnic clinical population of thrombolysed AIS 
patients, brain imaging signs of right and deep MCA territory lesions stroke predicted poor 
overall HRQoL.  While a variety of other imaging abnormalities - early ischemic change, 
MCA territory lesion, mass effect, large lesion, hyperattenuated/abnormal vessel sign, tissue 
hypoattenuation, and background changes - showed associations in univariate analyzes, they 
were not selected according to the pre-specified selection methods in multivariable analyzes 
with clinical factors for developing the optimal predictive model.  Signs of brain frailty – 
white matter change, atrophy and old infarcts - were each associated with most individual 
EQ-5D domains except anxiety/depression.  
Associations between a wide range of brain imaging abnormalities, including subcortical 
and/or brainstem infarcts[31], severe subcortical grey matter hyperintensities[32], and infarct 
volume[30], and poor HRQoL have been reported in several small studies[30-32].  Studies 
involving several hundred of patients have shown that acute infarct volume predicts quality 
of life, except cognition[29], lobar cerebral microbleeds predict physical function and social 
function[33], deep white matter hyperintensities are related to overall HRQoL after lacunar 
AIS[34], and cerebral small vessel disease is associated with reduced quality of life[35].  
However, all these studies used different questionnaires to measure HRQoL.  Although the 
EQ-5D is not specific to stroke, it is one of the most popular, simple and broadly accepted 
approaches to measuring HRQoL in stroke trials. 
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For patients with acute intracerebral hemorrhage, the findings of associations of hematomas 
located in the thalamus and infratentorial regions and poor HRQoL domains of mobility, self-
care and usual activity in the Intensive Blood Pressure Reduction in Acute Cerebral 
Haemorrhage Trial (INTERACT)[57], may reflect disruption of pyramidal tracts.  The 
finding that right hemisphere AIS is associated with poor HRQoL might be explained by a 
range of deficits; parietal sensory symptoms including neglect, visuo-spatial deficits 
impairing navigation and dressing and language deficits including loss of comprehension of 
the emotional content.  All of these features respond poorly to rehabilitation and if present, 
are likely to contribute to poor HRQoL[58, 59].  Another possible explanation is reduced 
efficacy of thrombolysis in right hemispheric AIS[60, 61] and the deep MCA territories[62] 
where reduced reperfusion could translate into reduced HRQoL.   
Strengths of our analyzes include the large sample, standardised measures and central blinded 
adjudication of brain imaging by trained assessors.  We also undertook a full process of 
prediction model development and validation of imaging factors.  Yet, our study was post-
hoc and limited to clinical trial data from thrombolyzed AIS patients of predominantly mild-
moderate neurological severity, and with few patients who received endovascular therapy 
which evolved of the study period.  Thus, selection bias was inevitable from these 
inclusion/exclusion criteria as well as from further exclusion of nearly one quarter of patients 
with missing scans or outcome, and from  comparisons showing several significantly 
different variables across included and excluded patients.  Another factor is that CT brain 
imaging significantly under-estimates early cerebral ischemia, and especially of the integrity 
of the pyramidal tracts, and also we did not include separate measurements of grey and white 
matter volumes.  Finally, in any observational analysis, the strength and direction of 
association may have been influenced by residual confounding from clinical and/or imaging 
features.   
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In conclusion, we found that right sided lesions and lesions including the deep volumes of the 
MCA location predicted poor overall HRQoL after AIS, whilst each background feature of 
brain frailty – atrophy, white matter change and old infarcts – is associated with adverse 
physical but not emotional HRQoL domains.  These findings may assist in understanding the 
disconnect between physical function and quality of life as a whole to maximise recovery and 
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Figure 1. Flowchart of patients included for analyzes 
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Table 1  Patient characteristics by level of health-related quality of life (HRQoL) 







Age, years 65.8 (56.8-74.4) 70.4 (61.6-78.3) <0.0001 
Male 1112/1717 (64.8) 444/809 (54.9) <0.0001 
Asian 1108/1717 (64.5) 450/809 (55.6) <0.0001 
Clinical measures    
  SBP 151 (135-164) 152 (137-168) 0.020 
  DBP 84 (76-93) 84 (76-93) 0.964 
  HR 78 (69-86) 78 (68-88) 0.732 
  NIHSS score 7 (4-11) 11 (6-16) <0.0001 
  GCS score 15 (14-15) 15 (13-15) <0.0001 
Medical history    
  Hypertension  1053/1716 (61.4) 535/809 (66.1) 0.021 
  Previous stroke 300/1717 (17.5) 136/809 (16.8) 0.682 
  Coronary artery disease 220/1716 (12.8) 131/809 (16.2) 0.022 
  Atrial fibrillation 269/1715 (15.7) 193/809 (23.9) <0.0001 
  Diabetes  300/1716 (17.5) 184/809 (22.7) 0.002 
  Hypercholesterolaemia  270/1716 (15.7) 182/809 (22.5) <0.0001 
  Current smoker 442/1715 (25.8) 182/808 (22.5) 0.078 
Pre-stroke modified Rankin scale score 1 251/1716 (14.6) 219/808 (27.1) <0.0001 
Medications    
  Antihypertensive agents 763/1716 (44.5) 419/809 (51.8) 0.001 
  Warfarin anticoagulation 35/1715 (2.0) 24/807 (3.0) 0.148 
  Aspirin or other antiplatelet agent 365/1715 (21.3) 231/807 (28.6) <0.0001 
  Glucose lowering agent(s) 195/1715 (11.4) 123/807 (15.2) 0.006 
  Statin or other lipid lowering agent 304/1714 (17.7) 196/807 (24.3) 0.0001 
Final diagnosis‡    
  Stroke mimic  65/1714 (3.8) 16/808 (2.0) 0.016 
  Stroke cause    
    Large artery occlusive etiology 578/1714 (33.7) 328/808 (40.6) 0.001 
    Small vessel disease  471/1714 (27.5) 116/808 (14.4) <0.0001 
    Cardioembolism  302/1714 (17.6) 200/808 (24.8) <0.0001 
    Other or uncertain etiology 298/1714 (17.4) 148/808 (18.3) 0.568 
Randomized to low-dose alteplase  861/1717 (50.2) 420/809 (51.9) 0.406 
Proxy respondent 566/1717 (33.0) 443/809 (54.8) <0.0001 
Brain imaging features    
  Acute ischaemic change  508/1717 (29.6) 313/809 (38.7) <0.0001 
  Side of ischaemic change     
    Right 209/1717 (12.2) 154/809 (19.0) <0.0001 
    Left 297/1717 (17.3) 159/809 (19.7) 0.151 
    Middle  4/1717 (0.2) 2/809 (0.3) 0.945 
  Classification of ischemic change     
    Grey/white matter cortex  304/1127 (27.0) 185/507 (36.5) 0.0001 
    Basal ganglia outline  243/1127 (21.6) 147/507 (29.0) 0.001 
    Hypodensity  341/1127 (30.3) 197/507 (38.9) 0.001 
  Location of ischemic lesion    
    MCA 488/1714 (28.5) 300/809 (37.1) <0.0001 
        Deep MCA 157/1714 (9.2) 94/809 (11.6) 0.054 
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        Left MCA 289/1717 (16.8) 153/809 (18.9) 0.217 
        Right MCA 200/1717 (11.7) 147/809 (18.2) <0.0001 
    ACA and/or PCA 15/1714 (0.9) 15/809 (1.9) 0.034 
    Infratentorial (cerebellum or brainstem) 10/1714 (0.6) 5/809 (0.6) 0.916 
  Mass effect 512/1717 (29.8) 318/809 (39.3) <0.0001 
  ASPECTS 8 (5-9) 8 (5-9) 0.740 
  ASPECTS >7 1497/1717 (87.2) 670/809 (82.8) 0.003 
  Large infarct 46/1707 (2.7) 43/803 (5.4) 0.001 
  Hyperattenuated/abnormal vessel sign 221/1714 (12.9) 158/809 (19.5) <0.0001 
  Tissue hypoattenuation 443/1712 (25.9) 264/809 (32.6) 0.0004 
  Any background damage 1210/1717 (70.5) 655/809 (81.0) <0.0001 
    Atrophy 995/1717 (58.0) 553/809 (68.4) <0.0001 
    Old infarct 563/1714 (32.9) 324/809 (40.1) 0.0004 
    White matter changes 492/1717 (28.7) 308/809 (38.1) <0.0001 
        Anterior white matter 414/1673 (24.8) 250/783 (31.9) 0.0002 
        Posterior white matter 329/1674 (19.6) 216/783 (27.6) <0.0001 
Data are n (%), or median (IQR).· P values are based on Chi-square or Mann-Whitney tests. 
ACA denotes anterior cerebral artery, ASPECTS Alberta Stroke Program Early CT Score, 
DBP diastolic blood pressure, GCS Glasgow coma scale, HR heart rate, HRQoL health 
related quality of life, MCA middle cerebral artery, SBP systolic blood pressure, NIHSS 
National Institute of Health Stroke Scale, mRS modified Rankin scale, PCA posterior cerebral 
artery  
*Level of HRQoL defined as good or poor according to >0.7 or ≤0.7 mean utility score on the 





Table 2 Associations between imaging features and poor HRQoL in training dataset 
 EQ-5D utility score*  Univariable  Model 7† 
Variables >0.7 (n=1145) ≤0.7 (n=540)  OR (95%CI) P value  OR (95%CI) P value 
Acute ischemic change 327/1145 (28.6) 213/540 (39.4)  1.63 (1.31-2.02) <0.0001    
Side of ischemic change         
  Right 132/1145 (11.5) 103/540 (19.1)  1.81 (1.37-2.40) <0.0001    
  Left 198/1145 (17.3) 110/540 (20.4)  1.22 (0.94-1.59) 0.128    
  Middle 1/1145 (0.1) 2/540 (0.4)  4.25 (0.39-47.0) 0.238    
Location of ischemic lesion         
  MCA 317/1143 (27.7) 204/540 (37.8)  1.58 (1.27-1.97) <0.0001    
    Left  193/1143 (16.9) 106/540 (19.6)  1.21 (0.93-1.57) 0.165    
    Right 126/1143 (11.0) 98/540 (18.2)  1.79 (1.35-2.39) <0.0001  1.46 (1.05-2.02) 0.02 
    Deep MCA 92/1143 (8.1) 70/540 (13.0)  1.70 (1.23-2.37) 0.002  1.50 (1.03-2.19) 0.03 
  ACA and/or PCA 9/1143 (0.8) 10/540 (1.9)  2.38 (0.96-5.88) 0.061    
  Infratentorial 4/1143 (0.4) 4/540 (0.7)  2.13 (0.53-8.53) 0.288    
Mass effect 330/1145 (28.8) 217/540 (40.2)  1.66 (1.34-2.06) <0.0001    
ASPECTS 7 (5-9) 8 (5-9)  1.04 (0.96-1.12) 0.368    
ASPECTS >7 991/1145 (86.6) 448/540 (83.0)  0.76 (0.57-1.00) 0.052    
Large infarct 32/1140 (2.8) 25/536 (4.7)  1.69 (0.99-2.89) 0.053    
Hyperattenuated/abnormal vessel sign  160/1143 (14.0) 102/540 (18.9)  1.43 (1.09-1.88) 0.010    
Tissue hypoattenuation 290/1142 (25.4) 178/540 (33.0)  1.45 (1.16-1.81) 0.001    
Markers of background damage 811/1145 (70.8) 437/540 (80.9S)  1.75 (1.36-2.24) <0.0001    
  Atrophy 677/1145 (59.1) 374/540 (69.3)  1.56 (1.25-1.94) <0.0001    
  White matter changes  318/1145 (27.8) 195/540 (36.1)  1.47 (1.18-1.83) 0.0005    
  Old infarct 363/1143 (31.8) 216/540 (40.0)  1.43 (1.161.77) 0.0009    
ACA denotes anterior cerebral artery, ASPECTS Alberta Stroke Program Early CT Score, CI confidence interval, EQ-5D 5-dimension European 
Quality of life scale HRQoL health related quality of life, MCA middle cerebral artery, OR odds ratio, PCA posterior cerebral artery  
*EQ-5D mean utility scores divided by >0.7 or ≤0.7 mean value 
†Model 7 consists of log odds of poor HRQoL = -1.658+0.099*age/10-0.255*Asian+0.094*National Institutes of Health stroke scale (NIHSS) 
score+0.186*diabetes mellitus+0.256*modified Rankin scale (mRS) score+0.355*proxy respondent +0.188*right MCA+0.204*deep MCA 
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Table 3.  Multivariable logistic regression analyses showing OR (95%CI) for associations of brain imaging features and dimensions 












Acute ischemic change 0.15 (0.01-1.84) 1.07 (0.07-16.74) 0.69 (0.06-8.59) 0.78 (0.07-8.70) 1.03 (0.09-12.35) 
Side of ischemic change      
  Right 1.30 (0.37-4.53) 0.51 (0.13-2.09) 0.68 (0.20-2.36) 1.74 (0.47-6.40) 1.33 (0.36-4.87) 
  Left 0.99 (0.29-3.43) 0.39 (0.10-1.60) 0.62 (0.18-2.15) 1.45 (0.40-5.33) 1.32 (0.36-4.83) 
  Middle 4.23 (0.32-55.4) 6.41 (0.32-127.79) 0.24 (0.02-2.89) 0.46 (0.03-7.35) 2.63 (0.20-34.15) 
Location of ischemic lesion      
  MCA 1.59 (0.26-9.88) 0.96 (0.12-7.64) 1.23 (0.19-7.82) 1.50 (0.28-8.05) 0.57 (0.09-3.62) 
  ACA and/or PCA 2.51 (0.46-13.75) 2.45 (0.37-16.30) 1.59 (0.29-8.74) 1.24 (0.27-5.60) 0.67 (0.12-3.62) 
  Infratentorial 0.99 (0.13-7.74) 0.12 (0.01-2.09) 1.65 (0.21-12.74) 1.74 (0.25-12.03) 0.21 (0.02-2.22) 
Mass effect 3.07 (0.92-10.28) 2.99 (0.95-9.40) 2.37 (0.70-8.04) 0.97 (0.31-2.99) 1.52 (0.53-4.35) 
ASPECTS >7 0.87 (0.62-1.23) 0.99 (0.69-1.42) 1.09 (0.77-1.55) 0.90 (0.64-1.27) 1.12 (0.79-1.57) 
Large infarct 0.89 (0.52-1.50) 1.14 (0.66-1.98) 1.15 (0.67-1.99) 1.26 (0.76-2.09) 1.23 (0.74-2.04) 
Hyperattenuated/abnormal vessel sign  0.90 (0.70-1.16) 1.17 (0.90-1.53) 1.27 (0.98-1.64) 1.07 (0.83-1.37) 1.21 (0.95-1.54) 
Tissue hypoattenuation 1.70 (1.08-2.68)§ 0.98 (0.61-1.57) 0.94 (0.59-1.50) 0.60 (0.39-0.93)§ 0.91 (0.58-1.41) 
Markers of background damage      
  Atrophy 1.24 (1.02-1.51)§ 1.26 (1.01-1.56)§ 1.33 (1.09-1.61)† 1.11 (0.91-1.36) 1.16 (0.96-1.42) 
  White matter changes  1.52 (1.25-1.86)* 1.29 (1.04-1.60)§ 1.26 (1.03-1.54)§ 1.13 (0.92-1.38) 1.17 (0.96-1.43) 
  Old infarct 1.13 (0.94-1.36) 1.24 (1.01-1.52)§ 1.34 (1.11-1.62)† 1.10 (0.91-1.34) 1.07 (0.89-1.29) 
ACA denotes anterior cerebral artery, ASPECTS Alberta stroke program early CT score, CI confidence interval, MCA denotes middle cerebral 
artery, OR odds ratio, PCA posterior cerebral artery,  
Models adjusted for baseline National Institutes of Health stroke scale (NIHSS) score and proxy respondent. 
*P < 0.0001 
†P<0.01 
§P<0.05 
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3310 patients were randomized in the 
alteplase-dose arm of the ENCHANTED trial 
13 patients were excluded: 
     9 No consent and data not used 
     1 Mistakenly randomized 
     3 Duplicate randomization 
3297 patients with useable data  
2843 had only CT 
91 had only MRI 
343 had both CT and MRI at baseline 
365 patients excluded due to missing 
baseline scans for adjudication 
2932 patients with baseline and follow up (if 
available) scans centrally adjudicated 
16 patients excluded with ineligible 
baseline scans  
2916 patients with available imaging data 
390 patients excluded with missing Day 
90 outcome EQ-5D data 
2526 patients included in analyzes 
